Garo H. Armen
Executive Chairman
$200,000
Investment in the 2019-2020 Convertible Note Offering on the same terms as all other investors.
| Officer | Age | In this role | Joined | 2023 pay | Source |
|---|---|---|---|---|---|
|
Alexander K. Arrow
Chief Financial Officer
|
54 |
Since 2016
10 years
|
Not stated | $150,000 | |
|
Andrew Slee
Chief Operating Officer
|
75 | Not stated | 2016 | Not reported | |
|
Garo H. Armen
Also a director
EXEC. CHAIR & PRINCIPAL OFF
Title from the Form 4 dated Aug 21, 2026
|
72 | Not stated | 2004 | $0 | |
|
Robert B. Stein
Director, Chief Medical Officer
|
74 | Not stated | 2016 | Not reported | |
|
Barrett Evans
Also a director
ex CEO
Title from the Form 3 dated May 15, 2025
|
Not stated | Not stated | Not stated | Not reported |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.
Investment in the 2019-2020 Convertible Note Offering on the same terms as all other investors.
Investment in the 2019-2020 Convertible Note Offering on the same terms as all other investors.
Assisted with slide decks, video editing, forecasting and market projections for investor presentations, compensated with stock option grants.
Consulting role assisting with clinical trial design.
Company uses a conference room at Agenus, Inc. office for board and shareholder meetings.
Loading...
